TESARO Announces Six Data Presentations at the 2016

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
TESARO Announces Six Data Presentations at the 2016 European Society for Medical Oncology (ESMO) Annual Meeting
  • Phase 3 results from ENGOT-OV16/NOVA trial of niraparib accepted for oral presentation during Presidential Symposium and inclusion in ESMO Press Programme
  • TESARO to webcast Investor and Analyst Briefing on Saturday, October 8

WALTHAM, Mass., Sept. 06, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO ), an oncology-focused biopharmaceutical company, today announced that data from six abstracts will be presented at the 2016 European Society for Medical Oncology (ESMO) annual meeting, October 7 to October 11, 2016, in Copenhagen. In addition, TESARO will webcast an investor and analyst briefing from Copenhagen on Saturday, October 8 at 7:00 PM local time in conjunction with the ESMO annual meeting.

Please plan to visit TESARO at Booth #415 for information about our pipeline.

Presentation Details (all times local):

Niraparib

Saturday, October 8, 2016, 4:30 PM to 6:00 PM – Presidential Symposium 1 A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial) Presentation: LBA3_PR, Presidential Symposium 1, Location: Copenhagen Room, Time: 5:30 PM Results selected for inclusion in the ESMO Press Programme

Sunday, October 9, 2016, 1:00 PM to 2:00 PM Modeling maintenance therapy in ovarian cancer Poster: 1043P, Location: Hall E

Niraparib is an investigational product candidate that has not been approved by any regulatory agencies.

Rolapitant

Sunday, October 9, 2016, 1:00 PM to 2:00 PM  Efficacy and safety of rolapitant in the prevention of chemotherapy-induced nausea and vomiting (CINV) in elderly patients Poster: 1441P, Location: Hall E

Sunday, October 9, 2016, 1:00 PM to 2:00 PM                                                             Efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with gastrointestinal and colorectal cancers  Poster: 1440P, Location: Hall E

Sunday, October 9, 2016, 1:00 PM to 2:00 PM Safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving Breast Cancer Resistant Protein (BCRP) substrate chemotherapy agents Poster: 1442P, Location: Hall E

Sunday, October 9, 2016, 1:00 PM to 2:00 PM Systematic review of the efficacy and safety of neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: identification of the relevant clinical trials Poster: 1443P, Location: Hall E

Rolapitant is marketed in the United States under trade name VARUBI®. Rolapitant has not been approved by any regulatory agencies outside of the United States.

Investor Briefing and Webcast TESARO will webcast an investor and analyst briefing in Copenhagen on Saturday, October 8 at 7:00 PM local time in conjunction with the ESMO annual meeting. At this briefing, TESARO management will review the niraparib development program and data presented at ESMO and answer questions from investors and analysts. This event will be webcast live and archived for 30 days, and may be accessed from the TESARO Investor Events and Presentations webpage at www.tesarobio.com .

About Niraparib Niraparib is an oral, once-daily PARP inhibitor that is currently being evaluated in four ongoing pivotal trials. TESARO is building a robust niraparib franchise by assessing activity across multiple tumor types and by evaluating several potential combinations of niraparib with other therapeutics. The ongoing development program for niraparib includes the Phase 3 trial in patients with recurrent ovarian cancer (the NOVA trial); a registrational Phase 2 treatment trial in patients with ovarian cancer (the QUADRA trial); a Phase 3 trial for the treatment of patients with BRCA-positive breast cancer (the BRAVO trial); and a Phase 3 trial in patients with first-line ovarian cancer (the PRIMA trial). Several collaborator-sponsored studies are also underway, including combination trials of niraparib plus pembrolizumab and bevacizumab. Janssen Biotech has licensed rights to develop and commercialize niraparib specifically for patients with prostate cancer worldwide, except in Japan.

About VARUBI® (Rolapitant) Rolapitant is marketed in the United States under trade name VARUBI®. VARUBI is a substance P/neurokinin-1 (NK-1) receptor antagonist indicated in the U.S. in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. VARUBI is contraindicated in patients receiving thioridazine, a CYP2D6 substrate. The inhibitory effect of a single dose of VARUBI on CYP2D6 lasts at least seven days and may last longer. Avoid use of pimozide; monitor for adverse events if concomitant use with other CYP2D6 substrates with a narrow therapeutic index cannot be avoided. Please see full prescribing information, including additional important safety information, available at www.varubirx.com .

An intravenous formulation of rolapitant is also being developed. TESARO licensed exclusive rights for the development, manufacture, commercialization, and distribution of VARUBI (rolapitant) from OPKO Health, Inc.

About TESARO TESARO is an oncology-focused biopharmaceutical company devoted to providing transformative therapies to people bravely facing cancer. For more information, visit www.tesarobio.com , and follow us on Twitter and LinkedIn .

 

Investor/Media Contact: Jennifer Davis Sr. Director, Corporate Development & Investor Relations +1.781.325.1116 or jdavis@tesarobio.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Steel Dynamics Gears Up for Q3 2026 Earnings Update

Updated Category News Views 6

Steel Dynamics Preps for Key Earnings Report Folks, we're staring down the barrel of another quarterly earnings report from Steel Dynamics, Inc., and you can bet this one is gonna have plenty of eyes glued. October 19th, 2026, that's when they'll peel back the curtain on how they fared in Q3. Now, buckle up, because this isn't just a numbers game—it’s a snapshot of...

Continue Reading
Raken Debuts Change Orders: A Game-Changer for Builds

Updated Category News Views 4

Construction Gets a Streamlined Boost with Raken's New Tool In construction, chaos often partners seamlessly with progress. But Raken is stepping in to shake things up a bit. This isn’t just another run-of-the-mill software update; this is Raken flexing its muscles in the construction tech arena. They’ve rolled out Change Orders, enhancing their project management...

Continue Reading
Protecting Your Family on Halloween: Safety Tips

Updated Category News Views 5

Avoid Turning Halloween Fun Into a Medical Emergency Halloween should be about ghosts and ghouls, not a dreaded detour to the ER. Yet, every year, adults and kids get carried away with costumes, only to find themselves in a real-life horror show courtesy of a slip, a fall, or a carving mishap. The American Academy of Orthopaedic Surgeons (AAOS) is waving the safety flag,...

Continue Reading
Striveworks: Boosting Army's AI Edge in Indo-Pacific

Updated Category News Views 6

The world keeps marching forward, and here’s Striveworks stepping up to the plate with another big move in the military tech space. This isn't your average partnership renewal; this involves a five-year, $200 million deal to enhance battlefield AI as the U.S. Army hones its modern warfare edge in the Indo-Pacific. Now, this isn't just a battle of strategies but a battle...

Continue Reading
Teamsters Secure Landmark Deal for SF Parking Workers

Updated Category News Views 4

Major Win for San Francisco's Parking Professionals Parking lots and garages across San Francisco might not be the first places you’d look for labor triumphs, but that’s exactly what almost 1,000 members of Teamsters Local 665 have achieved. Under a newly ratified four-year master contract, these parking pros snagged one of the richest deals the industry has seen. A...

Continue Reading
Newfold Digital Revamps Leadership for Growth Surge

Updated Category News Views 4

Steering into New Horizons with Fresh Leadership October 2026 marks a fresh chapter for Newfold Digital, as they shuffle the deck chairs a bit and ramp up for some ambitious growth endeavors. This web and commerce tech company decided it's time to bring a few heavy hitters on board. Starting this month, watch out for Sachin Puri taking the reins as Chief Executive...

Continue Reading
PrideStaff: 8 Years Strong on Franchise Times Top 400

Updated Category News Views 4

Where PrideStaff Stands in the Franchise Landscape Here's something the staffing world can't ignore: PrideStaff nailed it again, landing among the giants on the Franchise Times Top 400 for the eighth straight year. Sitting at number 217, this ain't just a lucky streak—this is a sustained homerun, my friends. Consistency Is Key, And They're Holding It Consider this...

Continue Reading
Full Sail University Bags Billboard Music School Honor

Updated Category News Views 6

Full Sail Scores a Billboard Nod — What's the Big Deal? Alright, Full Sail University just snagged a spot on Billboard Magazine's 2026 Top Music Business Schools list. That's no small fry, folks. This Florida institution has been carving out a niche in the music business education scene with a hands-on learning approach that hits the nail right on the head. The Recipe...

Continue Reading
Webull Faces Legal Scrutiny Over Chinese Ties

Updated Category News Views 5

The Unfolding Drama for Webull Shareholders When you see a ticker like NASDAQ:BULL rolling off your tongue these days, it’s not just about stock prices anymore—it's a whole saga wrapped in legal and geopolitical spice. Following the recent uproar from a House China committee report, Webull found itself thrust into the spotlight for all the wrong reasons. That report...

Continue Reading
Hexaware Teams with Anthropic for Game-Changing AI Move

Updated Category News Views 4

A Bold AI Partnership on the Horizon Mutual back-slapping or a deal with authentic grit? Hexaware’s latest tango with Anthropic might just be the jolt enterprises need. Announced under the flickering fluorescent lights of Mumbai, London, and Iselin, Hexaware’s multi-year partnership with Anthropic thrusts Claude, their razor-sharp AI, right into the mix of...

Continue Reading

Top 5 Most Recently Viewed Articles

Gelteq Ltd. Accelerates U.S. Nutraceutical Venture with Innovation

Updated Category News Views 131

Gelteq Ltd. Expands into the U.S. Nutraceutical Market Gelteq Limited, a leader in gel-based oral delivery solutions, is making waves as it expands its footprint in the U.S. nutraceutical landscape. Recent partnerships have led to exciting product launches facilitated by Gelteq’s proprietary technology, which aims to revolutionize how consumers experience wellness...

Continue Reading
Is the Pentagon Pizza Surge Just a Market Fluke or More?

Updated Category News Views 255

Pizza Traffic That Raises More Than Just Eyebrows Something's cooking near the Pentagon, and it’s not just the pepperoni. An account tracking pizza orders around military hubs just reported a surge in activity at a Papa John’s close to the Pentagon. Remember when Pete Hegseth snickered about this very notion? This isn't just a novelty; it's popping the lid off a wider...

Continue Reading
ibex Welcomes Karen Batungbacal to the Board of Directors

Updated Category News Views 243

ibex Appoints New Board Member to Enhance Leadership ibex Limited, a prominent name in global business process outsourcing and customer engagement technology, has recently announced an exciting addition to its Board of Directors. Karen Batungbacal, a significant figure in the outsourcing industry, will officially start her role on January 20, 2025. Experience that Drives...

Continue Reading
Kraton Focuses on Growth by Exiting Non-Core Operations

Updated Category News Views 343

Kraton Refocuses Strategy for Business Growth Kraton Corporation has recently announced a significant strategic decision to streamline its operations and prioritize its core business. This shift aims to enhance long-term growth and innovation within the company, particularly in the specialty polymers sector. Exiting the Dover Site As part of this strategic realignment,...

Continue Reading
Parkland Corp Sees Strong Q4 Performance Amid Strategic Review

Updated Category News Views 232

Strong Financial Performance in Q4 2024 Parkland Corporation has showcased a solid financial performance in the fourth quarter of 2024, achieving an adjusted EBITDA of $428 million and a full-year consolidated adjusted EBITDA of $1.69 billion. These results reflect a focus on operational efficiency and strategic growth amid a challenging market landscape. Despite...

Continue Reading